linjc16/ctgov huggingface dataset:
Immune Spatial Features of Guselkumab Cutaneous Response

Study Overview
=================
Brief Summary
-----------------
This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.

Detailed Description
-----------------
This is a one-arm, open-label study to examine the effect of Guselkumab . Guselkumab is a FDA-approved medication for the treatment of psoriasis. This study will examine how Guselkumab affects immune cells within scalp psoriasis lesions. Ten subjects with moderate to severe scalp psoriasis will be enrolled. Biopsy samples will be collected and undergo molecular profiling to correlate profiles with Guselkumab treatment response.

Official Title
-----------------
Immune Spatial Features of Guselkumab Cutaneous Response

Conditions
-----------------
Psoriasis of Scalp

Intervention / Treatment
-----------------
* Drug: Guselkumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: possess a PSSI (psoriasis scalp severity index) of ≥12 Exclusion Criteria: taking systemic immunosuppressives in the last 4 weeks pregnancy severe immunodeficiency (either from genetic or infectious causes). tuberculosis or other active serious infection active systemic malignancy. breast-feeding Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data. Males who are trying to conceive -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Guselkumab treatment<br>Guselkumab treatment for   9 months | Drug: Guselkumab<br>* Guselkumab treatment for   9 months<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in psoriasis scalp severity index score (PSSI) | PSSI measures the extent of psoriasis involvement and the severity of erythema, infiltration, and desquamation of the scalp. PSSI scores will be taken pre- and mid-treatment. Scores range from 0 to 72, with higher scores indicating more severity. | baseline and 9 months |
Mother-Baby Study - Relative Reinforcing Value (RRV)

Study Overview
=================
Brief Summary
-----------------
The study will test a model of biobehavioral mechanisms involved in the development of a system of emotion, attachment, and nutritive intake in the mother-infant dyad and the association of this system with maternal feeding behavior, child eating behavior, dietary intake, and adiposity.

Detailed Description
-----------------
This interventional task is done with children while they are in the long-term observational study, NCT06039878, at approximately ages 18 and 36 months. In the observational study there are 240 participants (120 mothers and 120 children). In this trial only data from the children is collected and therefore only 120 participants are listed.

Official Title
-----------------
Fundamental Biobehavioral Mechanisms Underlying the Integrated Development of Emotion, Attachment, and Nutritive Intake in the Mother-Infant Dyad

Conditions
-----------------
Eating Behavior

Intervention / Treatment
-----------------
* Behavioral: Relative Reinforcing Value of Food


Participation Criteria
=================
Eligibility Criteria
-----------------
The child is a participant in the observational study (NCT06039878).

Ages Eligible for Study
-----------------
Minimum Age: 0 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Relative Reinforcing Value<br>The researchers will enroll 120 children from the long-term observational study, NCT06039878. | Behavioral: Relative Reinforcing Value of Food<br>* Researcher gives child opportunity to press a button to earn three types of rewards: a high-reward food, a low-reward food, and a non-food reward.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relative Reinforcing Value (RRV) of food | The RRV is measured using the number of button presses for each reward type relative to other reward types | Up to approximately 36 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
eating behavior
Cannabis and Opioid Use Disorder

Study Overview
=================
Brief Summary
-----------------
This study plans to enroll participants with opioid use disorder who are not currently seeking treatment to assess the effects of cannabis on opioid withdrawal and other related outcomes.

Official Title
-----------------
Cannabis Modulation of Outcomes Related to Opioid Use Disorder: Opioid Withdrawal, Abuse Potential and Safety

Conditions
-----------------
Opioid Use Disorder

Intervention / Treatment
-----------------
* Drug: Inhaled vaporized cannabis
* Drug: Intransal opioid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Current opioid use disorder Exclusion Criteria: Current medical conditions that require medical management

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intranasal Opioid Agonist<br>Participants will receive non-therapeutic, experimental doses of an opioid agonist or placebo. Active opioid agonist/placebo will be administered once per session and will be administered intransally (snorting). | Drug: Inhaled vaporized cannabis<br>* Double-blind cannabis and placebo doses, administered through vaporizer<br>Drug: Intransal opioid<br>* Double-blind opioid and placebo doses, administered intranasal route<br>|
| Experimental: Vaporized cannabis<br>Participants will receive non-therapeutic, experimental doses of active or placebo vaporized cannabis. Active cannabis/placebo will be administered once per session and will be administered via a vaporizer. | Drug: Inhaled vaporized cannabis<br>* Double-blind cannabis and placebo doses, administered through vaporizer<br>Drug: Intransal opioid<br>* Double-blind opioid and placebo doses, administered intranasal route<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Baseline - Opioid Withdrawal Severity - Visual Analog Scale (VAS) | Subjective ratings of opioid withdrawal severity on visual analog scale (scale 0-100; 0 = not at all, 100 = extremely) | Change from baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Baseline - Opioid Drug Liking - Visual Analog Scale (VAS) | Subjective ratings of drug liking on visual analog scale (scale 0-100, 0 = not at all, 100 = extremely) | Change from baseline | 
| Change from Baseline - Respiration | Physiological monitoring of respiration rate (breaths per minute) | Change from baseline |
Navigating the Clinical Research Process for Glioma

Study Overview
=================
Brief Summary
-----------------
Participation in medical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups. This trial will admit a wide range of data on the clinical trial experience of glioma patients to determine which factors prevail in limiting a patient's ability to join or finish a trial. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future glioma patients.

Official Title
-----------------
Study on Glioma Patients: Understanding Their Glioma Clinical Trial Experiences

Conditions
-----------------
Glioma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed diagnosis of glioma Participant must be 18 years of age or older Participant must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and other requirements of the study. Exclusion Criteria: Pregnant or lactating woman Participant is actively receiving study therapy in another Inability to provide written informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of patients who decide to enroll in a glioma clinical research. |  | 3 months | 
| Number of glioma study participants who remain in clinical study until completion. |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
glioma
Re-Adjustment of Sweep Gas Flow to the During the Rewarming Period of the Cardiopulmonary Bypass

Study Overview
=================
Brief Summary
-----------------
The investigators designed this prospective observational study with the theory that alkalosis caused by decreased CO2 solubility due to temperature increase during the rewarming period of the Cardiopulmonary Bypass could be prevented by reducing the sweep gas flow during the rewarming period.

Official Title
-----------------
Re-Adjustment of Sweep Gas Flow to the During the Rewarming Period of the Cardiopulmonary Bypass to Prevent Alkalosis

Conditions
-----------------
Optimal Sweep Gas Flow, Determination of Optimal Sweep Gas Flow for Different Phases of Cardiopulmonary Bypass

Intervention / Treatment
-----------------
* Other: Gas Flow Adjustment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over 18 years of age Elective CPB surgery Exclusion Criteria: Patients undergoing minimally invasive surgery Patients undergoing robotic cardiac surgery, Patients undergoing deep hypothermia, Patients undergoing total circulatory arrest, Patients whose FiO2 requirement is high that cannot be applied to target gas flow

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br>Sweep Gas Flow did not changed (1.35 L/m2/min) | |
| Group 2<br>Sweep Gas Flow decreased during rewarming (1.2 L/m2/min) | Other: Gas Flow Adjustment<br>* Decreased gas flow causes PaCO2 to elevate and prevents alkalosis<br>|
| Group 3<br>Sweep Gas Flow decreased during rewarming (1 L/m2/min) | Other: Gas Flow Adjustment<br>* Decreased gas flow causes PaCO2 to elevate and prevents alkalosis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Arterial pH lever lower than 7.30 | maintaining physiological pH | during the cardiopulmonary bypass and postoperative 24th hour | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| rSO2 20% below initial value | observing the rSO2 of brain during rewarming period | during the cardiopulmonary bypass | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sweep gas flow, rewarming, cardiopulmonary bypass, alkalosis
Validity and Reliability of the GPCOG -TR

Study Overview
=================
Brief Summary
-----------------
The General Practitioner assessment of Cognition (GPCOG) was specifically developed as a brief cognitive screening tool to be used by general practitioners (GPs). It consists of a patient section testing cognition and an informant section asking historical questions. The aim of this study was to test the validity and reliability of the Turkish version of GPCOG-TR on Turkish older adults.

Official Title
-----------------
Validity and Reliability of the Turkish Version of General Practitioner Assessment of Cognition

Conditions
-----------------
Dementia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age: least 55 years old Provide informed consent Diagnosed with dementia ( patient group) Exclusion Criteria: Living in a nursing home Presence of psychiatric disorders requiring treatment Presence of other comorbidity interfering with cognitive performance such as severe chronic heart failure, chronic obstructive pulmonary disease, diabetes, anemia Impairment of auditory or visual perception Low education Known cognitive impairment (for control group only) Lack of a reliable informant.

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patient group<br>who diagnosed with dementia | |
| Control group<br>who diagnosed as healthy (don't have dementia) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Clinical Dementia Rating score (CDR) | The scoring system from 0 to 3 ( 0 means healthy while 3 Severe dementia ) | 1-2 hrs | 
| the General Practitioner Cognitive Assessment tool (GPCOG-TR) | Total score: 15 9 for the patient part 6 for the informant part ( The lower the score the more serious is the cognition is) | 10 min | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Mini-mental State Examination (MMSE) | Total score : 30 Scores of 25-30 out of 30 are considered normal, 21-24 as mild, 10-20 as moderate and below 10 as severe impairment. | 10 min | 
| Alzheimer's Disease Assessment Scale-Cognitive scale (ADAS-Cog) | The total ADAS-Cog score ranges from 0-70 with higher scores suggesting greater impairment. | 30 min | 
| Geriatric Depression Scale (GDS) | Total score : 15 0-4 are considered normal, depending on age, education, and complaints; 5-8 indicate mild depression; 9-11 indicate moderate depression; and 12-15 indicate severe depression. | 5 min | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
General Practitioners, Early diagnosis
Prevalence of Peripheral Vascular Diseases and Presentation in Patients With Autoimmune Diseases

Study Overview
=================
Brief Summary
-----------------
Rheumatic autoimmune diseases include conditions such as systemic lupus rheumatoid arthritis systemic sclerosis in which connective tissues are frequently targeted. Autoimmune diseases as a group are among the leading causes of death and morbidity in the industrial world and pose an immense socioeconomic burden despite the considerable accumulative burden of these diseases only a small number of multinational registries for a few selected autoimmune diseases have been devised. Numerous autoimmune inflammatory diseases have been associated with various forms of vasculopathy and increase vascular disease risk such as accelerated atherogenesis and thromboembolic events as digital and acral gangrene secondary Raynaud syndrome arterial aneurysm and different cutaneous ulcer. The etiopathogenesis os increased risk of peripheral vascular diseases and presentation in autoimmune diseases is not entirely clear but multiple contibutors have been explored especially in the context of systemic inflammation and disordered thrombogenesis.

Official Title
-----------------
Prevalence of Peripheral Vascular Diseases and Presentation in Patients With Autoimmune Diseases

Conditions
-----------------
Peripheral Vascular Diseases and Presentation in Patient With Autoimmune Diseases

Intervention / Treatment
-----------------
* Other: cross sectional study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all ages Both sexes Recent or past history of vascular diseases or presentation in any proven autoimmune diseases according to the guidlines. Exclusion Criteria: patients refuse the study patients do not have established diagnosis of vascular diseases . patients not completely approved to have autoimmune diseases.
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: cross sectional study|cross sectional study to explore magnitude of peripheral vascular diseases and presentations in patients with autoimmune diseases in sohag society.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prevalence of peripheral vascular diseases and presentations in patients with autoimmune diseases . | old and new vascular diseases and presentations in patients with autoimmune diseases | 6 months |
Total Motile Sperm Count and Pregnancy Rate From Intrauterine Insemination

Study Overview
=================
Brief Summary
-----------------
Intrauterine insemination (IUI) is one of the most important infertility treatments. Infertility is failure to establish pregnancy (>12 months) with regularly unprotected sexual intercourse. Post-wash total motile sperm count (TMSC) vaguely defined as a predictor of IUI pregnancy rate. The minimum value required is also not clear. This study aimed to further define the relationship and determine the minimum recommended value to achieve a satisfactory IUI pregnancy rate. Post-wash TMSC is predictive of IUI success. No optimal cut-off could be identified. In conclusion, post-wash TMSC is highly suggested as a quantitative predictor along with others in counseling and informed consent. The recommended threshold value is >3 x 106.

Official Title
-----------------
Effect of Post-Wash Total Motile Sperm Count on the Pregnancy Rate of Infertility Patients Undergoing Intrauterine Insemination

Conditions
-----------------
Insemination

Intervention / Treatment
-----------------
* Procedure: Intrauterine insemination


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: post-wash total motile sperm count needed to be over 5 x 10^5 Exclusion Criteria: missing data on pregnancy outcome and missing medical records
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Intrauterine insemination<br>Patients undergoing intrauterine insemination | Procedure: Intrauterine insemination<br>* Transfer of sperm into the fallopian tube through a specialised cannula<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pregnancy rate | Pregnancy number divided by number of IUI cycles | max 9 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
infertility, intrauterine insemination, post-wash total motile sperm count
Madany Closure: A Novel Technique for Fascial Closure in Laparoscopic Surgery

Study Overview
=================
Brief Summary
-----------------
this study aims to evaluate the effectiveness of the use of a basic laparoscopic instrument (Only needle holder) with a new technique for port site closure

Official Title
-----------------
Madany Closure: A Novel Technique for Fascial Closure in Laparoscopic Surgery

Conditions
-----------------
Cholecystolithiasis

Intervention / Treatment
-----------------
* Procedure: Madany Closure
* Procedure: Standard closure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age . 18 years eligible for Laparoscopic cholecystectomy Exclusion Criteria: refused to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Madany closure<br>the novel port site closure technique is to be done for this group | Procedure: Madany Closure<br>* Madany Closure is a new technique for the porte site closure<br>|
| Active Comparator: Control<br>external closure of the port site | Procedure: Standard closure<br>* Standard closure technique of the port site from ecternal<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| closure time | closure time in seconds | 1 day | 
| rate of closure failure | rate failure to close the port site | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of port site infection | incidence of infection of the port site | 1 month | 
| incidence of port site hernia | incidence of hernia at the port site | 6 weeks |